{"id":129397,"date":"2025-05-30T06:17:20","date_gmt":"2025-05-30T05:17:20","guid":{"rendered":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/"},"modified":"2025-05-30T06:17:20","modified_gmt":"2025-05-30T05:17:20","slug":"sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela","status":"publish","type":"post","link":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/","title":{"rendered":"Sanidad financia Tofersen, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1126.jpg\" \/><\/p>\n<p>El <a href=\"https:\/\/www.sanidad.gob.es\/\" target=\"_blank\" rel=\"noopener\">Ministerio de Sanidad<\/a>, a trav\u00e9s de la <strong>Comisi\u00f3n Interministerial de Precios de los Medicamentos (CIPM)<\/strong>, ha aprobado la financiaci\u00f3n de <strong>Tofersen<\/strong>, un <strong>tratamiento<\/strong> innovador <strong>para la esclerosis lateral amiotr\u00f3fica (ELA)<\/strong>, comercializado bajo el nombre de <strong>Qalsody\u00ae<\/strong>. Con esta decisi\u00f3n, Espa\u00f1a se sit\u00faa entre los primeros pa\u00edses europeos en incorporar esta terapia al sistema p\u00fablico de salud.<\/p>","protected":false},"excerpt":{"rendered":"<p>El Ministerio de Sanidad, a trav\u00e9s de la Comisi\u00f3n Interministerial de Precios de los Medicamentos (CIPM), ha aprobado la financiaci\u00f3n de Tofersen, un tratamiento innovador para la esclerosis lateral amiotr\u00f3fica (ELA), comercializado bajo el nombre de Qalsody\u00ae. Con esta decisi\u00f3n, Espa\u00f1a se sit\u00faa entre los primeros pa\u00edses europeos en incorporar esta terapia al sistema p\u00fablico [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[5],"tags":[],"class_list":["post-129397","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.9 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanidad financia Tofersen, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA - bip4ex<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanidad financia Tofersen, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA\" \/>\n<meta property=\"og:description\" content=\"El Ministerio de Sanidad, a trav\u00e9s de la Comisi\u00f3n Interministerial de Precios de los Medicamentos (CIPM), ha aprobado la financiaci\u00f3n de Tofersen, un tratamiento innovador para la esclerosis lateral amiotr\u00f3fica (ELA), comercializado bajo el nombre de Qalsody\u00ae. Con esta decisi\u00f3n, Espa\u00f1a se sit\u00faa entre los primeros pa\u00edses europeos en incorporar esta terapia al sistema p\u00fablico [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/\" \/>\n<meta property=\"og:site_name\" content=\"bip4ex\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-30T05:17:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1126.jpg\" \/>\n<meta name=\"author\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/\"},\"author\":{\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\"},\"headline\":\"Sanidad financia Tofersen, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA\",\"datePublished\":\"2025-05-30T05:17:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/\"},\"wordCount\":80,\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/infosalut\\\/epr1126.jpg\",\"articleSection\":[\"Noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/\",\"name\":\"Sanidad financia Tofersen, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA - bip4ex\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/infosalut\\\/epr1126.jpg\",\"datePublished\":\"2025-05-30T05:17:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/infosalut\\\/epr1126.jpg\",\"contentUrl\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/infosalut\\\/epr1126.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanidad financia Tofersen, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"name\":\"bip4ex\",\"description\":\"Vigilancia Tecnol\u00f3gica\",\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\",\"name\":\"Helloproject.es\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"contentUrl\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"width\":322,\"height\":365,\"caption\":\"Helloproject.es\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\",\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/author\\\/luismi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanidad financia Tofersen, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA - bip4ex","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/","og_locale":"es_ES","og_type":"article","og_title":"Sanidad financia Tofersen, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA","og_description":"El Ministerio de Sanidad, a trav\u00e9s de la Comisi\u00f3n Interministerial de Precios de los Medicamentos (CIPM), ha aprobado la financiaci\u00f3n de Tofersen, un tratamiento innovador para la esclerosis lateral amiotr\u00f3fica (ELA), comercializado bajo el nombre de Qalsody\u00ae. Con esta decisi\u00f3n, Espa\u00f1a se sit\u00faa entre los primeros pa\u00edses europeos en incorporar esta terapia al sistema p\u00fablico [&hellip;]","og_url":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/","og_site_name":"bip4ex","article_published_time":"2025-05-30T05:17:20+00:00","og_image":[{"url":"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1126.jpg","type":"","width":"","height":""}],"author":"Luis Miguel Mej\u00edas Ramos","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Luis Miguel Mej\u00edas Ramos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/#article","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/"},"author":{"name":"Luis Miguel Mej\u00edas Ramos","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca"},"headline":"Sanidad financia Tofersen, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA","datePublished":"2025-05-30T05:17:20+00:00","mainEntityOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/"},"wordCount":80,"publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/#primaryimage"},"thumbnailUrl":"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1126.jpg","articleSection":["Noticias"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/","url":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/","name":"Sanidad financia Tofersen, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA - bip4ex","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/#website"},"primaryImageOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/#primaryimage"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/#primaryimage"},"thumbnailUrl":"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1126.jpg","datePublished":"2025-05-30T05:17:20+00:00","breadcrumb":{"@id":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/#primaryimage","url":"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1126.jpg","contentUrl":"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1126.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/helloproject.es\/vigilancia\/sanidad-financia-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/helloproject.es\/vigilancia\/"},{"@type":"ListItem","position":2,"name":"Sanidad financia Tofersen, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA"}]},{"@type":"WebSite","@id":"https:\/\/helloproject.es\/vigilancia\/#website","url":"https:\/\/helloproject.es\/vigilancia\/","name":"bip4ex","description":"Vigilancia Tecnol\u00f3gica","publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/helloproject.es\/vigilancia\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/helloproject.es\/vigilancia\/#organization","name":"Helloproject.es","url":"https:\/\/helloproject.es\/vigilancia\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/","url":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","contentUrl":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","width":322,"height":365,"caption":"Helloproject.es"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca","name":"Luis Miguel Mej\u00edas Ramos","url":"https:\/\/helloproject.es\/vigilancia\/author\/luismi\/"}]}},"_links":{"self":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/129397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/comments?post=129397"}],"version-history":[{"count":0,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/129397\/revisions"}],"wp:attachment":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/media?parent=129397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/categories?post=129397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/tags?post=129397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}